Oaktree Acquisition Corp. III Life Sciences: general meeting postponed to Oct 23

What happened

• Oaktree Acquisition Corp. III Life Sciences filed a definitive proxy statement on Oct 2, 2026 for an extraordinary general meeting in lieu of an annual meeting scheduled for Oct 16, 2026 to consider a proposal to extend the date to complete an initial business combination.
• On Oct 16, 2026, the extension committee of the board approved the postponement of that general meeting to Oct 23, 2026, prior to the time at which the meeting was scheduled to be held, to permit further solicitation and vote of proxies. The rescheduled general meeting will be held on Oct 23, 2026 at 10:00 a.m., Eastern Time, at Kirkland & Ellis LLP, 601 Lexington Avenue, New York, NY 10022, and via a virtual meeting.

Key details

• Record date remains close of business on Sep 22, 2026; only holders of record on that date are entitled to notice and to vote.
• Proxies previously submitted for the Oct 16, 2026 meeting remain valid and will be voted at the rescheduled meeting unless properly revoked; shareholders who already voted do not need to act unless they wish to change their vote.
• In-person attendance requires a reservation by contacting the CEO at info@oaktreeacquisitioncorp.com by 10:00 a.m., Eastern Time, on Oct 21, 2026; online attendance, voting and questions are available at https://www.cstproxy.com/oac-iii/2026.
• Shareholders may continue to request withdrawal of redemptions of Class A ordinary shares by contacting Continental Stock Transfer & Trust Company at spacredemptions@continentalstock.com until the rescheduled meeting. The proxy materials were accompanied by OAC’s Form 10-K for the year ended Dec 31, 2025 and are available on the SEC website.

Why it may matter

• Item reported: Item 7.01 (Regulation FD disclosure). The filing discloses the postponement of the general meeting and provides related meeting logistics, voting and solicitation information. The filing does not show why the company acted.